DailyTimeCapsule brief
July 27, 1999
On July 27, 1999, a significant spending spree by a major tobacco company in Albany drew attention, highlighting the industry's ongoing influence in the political and economic landscape of the United States. This coincided with broader public health discussions as a government agency announced plans to ask Congress to drop a controversial gasoline additive associated with environmental concerns. Meanwhile, the editorial world faced turmoil as the editor of a prominent medical journal was forced to resign amid disputes concerning the marketing of the journal's name, raising questions about ethical standards in medical publishing. At this time, the nation was grappling with the implications of the tobacco settlement achieved the previous year, and debates over public health regulations were intensifying.
Key developments
-
In an aggressive lobbying campaign, Philip Morris Cos, the world's largest cigarette manufacturer, has invested significantly in gaining influence among New York State lawmakers. They have reportedly spent tens of thousands of dollars on gifts and other incentives aimed at swaying legislative decisions in their favor. This effort forms part of a broader strategy to counter proposed regulations that could impact their business operations.
-
The Environmental Protection Agency (EPA) is set to propose to Congress the discontinuation of a mandate requiring oil companies to use methyl tertiary butyl ether (MTBE) as an additive in gasoline. This decision arises from concerns that while MTBE was intended to improve air quality, it has been found to contaminate drinking water supplies, leading to significant public health risks. A special panel is expected to recommend this change, emphasizing the need to balance environmental protection with the safety of water resources.
-
Dr. Jerome P. Kassirer, the esteemed editor of The New England Journal of Medicine, has made the decision to resign following disputes with the Massachusetts Medical Society regarding the commercialization of the journal's name. The controversy centers around the Society's plans to leverage the journal's prestigious brand in the expansion of its publishing operations, raising ethical concerns over the integrity of medical journalism. The resignation has sparked discussions in the medical community about the balance between commercial interests and the core mission of medical publications.